Receptos Inc (NASDAQ:RCPT)

Data as of Oct 17
 +3.20 / +5.24%
Today’s Change
Today|||52-Week Range
Health Technology
Pharmaceuticals: Other

Company Description

Receptos, Inc. is a biopharmaceutical company. It discovers, develops and commercializes innovative therapeutics for immune disorders. The company clinical pipeline includes RPC1063 and RPC4046. The RPC1063 is being developed as an oral therapy for the treatment of relapsing multiple sclerosis (RMS) and inflammatory bowel disease (IBD). The RPC4046 developed for the treatment of an allergic/immune-mediated disorder, eosinophilic esophagitis (EoE), which is an orphan disease. Receptos was founded by Marcus F. Boehm, Robert J. Peach, William H. Rastetter, Hugh Rosen and Raymond C. Stevens on September 26, 2008 and is headquartered in San Diego, CA.

Contact Information

Receptos, Inc.
10835 Road to the Cure
San Diego California 92121
P:(858) 652-5700
Investor Relations:



Other institutional44.16%
Mutual fund holders40.06%
Individual stakeholders27.76%

Top Executives

Faheem HasnainPresident, Chief Executive Officer & Director
Graham K. CooperCFO, Head-Investor & Media Relations
David A. HinkleCAO, Finance Director & Controller
Robert J. PeachChief Scientific Officer
Marcus F. BoehmChief Technology Officer

To view my watchlist

Not a member yet?

Sign up now for a free account
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.